FOLR3 and urinary bladder carcinoma: FOLR3 is highly overexpressed on several tumor cells, including ovarian, nonsmall cell lung, kidney, brain, endometrial, colorectal, breast, pancreatic, gastric, prostate, testicular, and bladder cancer; thus, it is known as therapeutic target for cancer treatment (22–24).